Table 3.
Proportion of CD3+CD4+ blood lymphocytes coated with ICs (IgG, IgM, C3d, gp120) and stained with CD95L grouped according to suggested pathomechanism
| % Positive cells (median) in | |||
|---|---|---|---|
| Parameter | Patients (n = 11) | Controls (n = 10) | P |
| ADCC, complement lysis | |||
| CD3+CD4+IgG+PI+ | 3·7 (8·0) | 0·3 (0·2) | 0·00001 |
| CD3+CD4+IgM+PI+ | 5·3 (8·7) | 0·4 (0·6) | 0·000006 |
| CD3+CD4+C3d+PI+ | 3·5 (7·9) | 0·4 (0·5) | 0·000006 |
| CD3+CD4+gp120+PI+ | 1·5 (4·5) | 0·6 (0·6) | 0·00004 |
| CD3+CD4+IgG+CD95L– | 3·9 (6·1) | 1·9 (1·1) | 0·008 |
| CD3+CD4+IgM+CD95L– | 6·4 (15·4) | 1·5 (0·9) | 0·0003 |
| CD3+CD4+C3d+CD95L– | 13·9 (62·7) | 2·8 (1·8) | 0·000006 |
| CD3+CD4+gp120+CD95L– | 3·6 (1·9) | 2·1 (1·7) | 0·004 |
| CD3+CD4+PI+CD95L– | 1·9 (2·2) | 1·6 (0·7) | 0·5 |
| Anti-CD95-induced apoptosis, phagocytosis | |||
| CD3+CD4+IgG+PI– | 9·1 (10·5) | 2·5 (2·3) | 0·001 |
| CD3+CD4+IgM+PI– | 17·8 (18·9) | 2·3 (1·9) | 0·0002 |
| CD3+CD4+C3d+PI– | 24·2 (31·2) | 4·0 (1·5) | 0·0001 |
| CD3+CD4+gp120+PI– | 6·5 (13·8) | 2·6 (4·4) | 0·04 |
| CD3+CD4+CD95+PI– | 55·8 (16·3) | 44·4 (15·8) | 0·04 |
| CD95L-induced apoptosis | |||
| CD3+CD4+CD95+PI+ | 6·5 (5·9) | 1·4 (0·9) | 0·00002 |
| CD3+CD4+PI–CD95L+ | 5·6 (10·3) | 2·7 (10·3) | 0·1 |
| CD3+CD4+PI+CD95L+ | 6·0 (11·6) | 4·3 (5·7) | 0·2 |
| CD3+CD4+IgG+CD95L+ | 4·6 (15·5) | 0·8 (1·0) | 0·0001 |
| CD3+CD4+IgM+CD95L+ | 5·5 (11·1) | 1·4 (1·5) | 0·002 |
| CD3+CD4+C3d+CD95L+ | 8·7 (16·2) | 1·1 (1·9) | 0·001 |
| CD3+CD4+gp120+CD95L+ | 5·3 (9·6) | 1·5 (1·3) | 0·005 |
| CD3+CD4+IgG–CD95L+ | 2·7 (2·3) | 0·8 (0·3) | 0·0004 |
| CD3+CD4+IgM–CD95L+ | 2·4 (3·1) | 1·8 (2·1) | 0·9 |
| CD3+CD4+C3d–CD95L+ | 1·4 (2·4) | 0·6 (0·5) | 0·07 |
| CD3+CD4+gp120–CD95L+ | 1·9 (2·0) | 0·4 (0·5) | 0·0001 |
| IC-independent necrosis | |||
| CD3+CD4+IgG–PI+ | 8·5 (5·6) | 3·4 (3·0) | 0·00007 |
| CD3+CD4+IgM–PI+ | 6·9 (4·5) | 2·7 (1·6) | 0·001 |
| CD3+CD4+C3d–PI+ | 4·8 (1·9) | 3·0 (1·5) | 0·008 |
| CD3+CD4+gp120–PI+ | 9·1 (5·2) | 2·9 (2·8) | 0·0003 |
| CD3+CD4+CD95–PI+ | 3·7 (3·7) | 2·2 (2·8) | 0·04 |
| Viable lymphocytes | |||
| CD3+CD4+IgG–CD95L– | 84·9 (16·6) | 96·1 (2·3) | 0·000006 |
| CD3+CD4+IgM–CD95L– | 79·1 (26·7) | 94·2 (3·6) | 0·001 |
| CD3+CD4+C3d–CD95L– | 69·4 (68·3) | 94·7 (2·1) | 0·000006 |
| CD3+CD4+gp120–CD95L– | 88·2 (11·1) | 95·9 (1·9) | 0·0004 |
| CD3+CD4+PI–CD95L– | 85·4 (31·1) | 91·3 (15·6) | 0·05 |
| CD3+CD4+IgG–PI– | 75·6 (12·5) | 93·8 (3·4) | 0·000006 |
| CD3+CD4+IgM–PI– | 71·4 (24·5) | 94·7 (4·2) | 0·000006 |
| CD3+CD4+C3d–PI– | 67·5 (33·0) | 93·2 (2·0) | 0·000006 |
| CD3+CD4+gp120–PI– | 84·8 (17·5) | 93·8 (6·0) | 0·0004 |
| CD3+CD4+CD95–PI– | 26·9 (22·3) | 53·0 (11·6) | 0·00004 |
P-values were calculated using Mann–Whitney U-test. Adjustment for multiple testing was performed according to the method of Bonferroni (n = 40). P-values of ≤0·001 are considered significant and are shown in bold type. The interquartile range of each parameter is given in brackets.